GRID2 and endometrial carcinoma: Abnormal expression of GRID2 has not been reported in any cancer experiments. However, Chen et al. suggested that GRID2 was significantly downregulated in endometrial carcinoma, and its expression was significantly associated with the proliferation and invasion of cancer cells through bioinformatics analysis. In this study, it was shown that GRID2 was significantly downregulated in the overall- and early-stage STAD, indicating that GRID2 might be a novel biomarker of these two stages of STAD